Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.-Reference-Cited by-同舟云学术

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

Published:1987-12-12 Issue:6612 Volume:295 Page:1509-1512
ISSN:0959-8138
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Kontoghiorghes G J,Aldouri M A,Hoffbrand A V,Barr J,Wonke B,Kourouclaris T,Sheppard L

Publisher

BMJ

Subject

General Earth and Planetary Sciences,General Environmental Science,General Engineering

Reference29 articles.

1. Continuous subcutaneous administration of desferrioxamine in patients with iron overload;RD, I.Propper; B, Cooper; RR, Rufo;N EnglJ Med,1977

2. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload;Hussain, M.A.M.; Flynn, D.M.; Green, N.; Hussein, S.; Hoffbrand, A.V.;Lancet,1976

3. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxanine infusions;Oliviery, N.F.; Buncic, R.J.; Chew, E.;N EnglJ Med,1986

4. Iron chelation with oral desferrioxamine;Callender, S.T.; Weatherall, D.J.;Lancet,1980

5. Desferrioxamine suppositories;Kontoghiorghes, G.J.; Marcus, R.E.; Huehns, E.R.;Lancet,1983

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites;International Journal of Molecular Sciences;2024-05-09

2. Minimizing higher-order aggregation maximizes iron mobilization by small molecules;Nature Chemical Biology;2024-04-25

3. Article review: Brazilin as potential anticancer agent;Frontiers in Pharmacology;2024-03-07

4. Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs;International Journal of Molecular Sciences;2023-11-25

5. The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases;Pharmaceuticals;2023-07-18